References
- Modi CM, Mody SK, Patel HB, et al. Toxicopathological overview of analgesic and anti-inflammatory drugs in animals. J Appl Pharm Sci 2012;2:149–57.
- Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 2003;38:645–59.
- Crofford LJ, Wilder RL, Ristimäki A, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095
- Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996;10:1–15.
- Kulkarni S, Singh V. Positioning dual inhibitors in the treatment of pain and inflammatory disorders. Inflammopharmacology 2008;16:1–15.
- Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063–73.
- Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006;38:1654–61.
- McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des 2000;6:1693–724.
- Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000;59:1207–16.
- Greenberg J, Fisher M, Kremer J, et al. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol 2009;27:395.
- Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954–9.
- Shishoo CJ, Pathak US, Rathod IS, et al. Synthesis and pharmacological evaluation of some novel 5-aryl-6-arylamino-l-phenylpyrazolo [3, 4-d] pyrimidin-4 (5H)-ones as analgesic and antiinflammatory agents. Ind J Chem Sec B 1999;38:684–95.
- Yadava U, Singh M, Roychoudhury M. Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2: insight from molecular docking studies. J Biol Phys 2013;39:419–38.
- Raffa D, Maggio B, Plescia F, et al. Pyrazolo[3,4-d]pyrimidine derivatives as COX-2 selective inhibitors: synthesis and molecular modelling studies. Arch Pharm (Weinheim) 2009;342:321–6.
- Yewale SB, Ganorkar SB, Baheti KG, Shelke RU. Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents. Bioorg Med Chem Lett 2012;22:6616–20.
- Abdelazeem AH, Abdelatef SA, El-Saadi MT, et al. Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents. Eur J Pharm Sci 2014;62:197–211.
- Abdellatif KRA, Lamie PF, Omar HA. 3-Methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents. J Enzyme Inhib Med Chem 2016;31:318–24.
- Abdellatif KRA, Abdelall EKA, Fadaly WA, Kamel GK. Synthesis, cyclooxygenase inhibition and anti-inflammatory evaluation of novel diarylheterocycles with a central pyrazole, pyrazoline or pyridine ring. Med Chem Res 2015;24:2632–44.
- Abdellatif KRA, Elshemy HAH, Salama SA, Omar HA. Synthesis, characterization and biological evaluation of novel 4′-fluoro-2′-hydroxy-chalcones derivatives as antioxidant, anti-inflammatory and analgesic agents. J Enz Inhib Med Chem 2015;30:484–91.
- Abdellatif KRA, Chowdhury MA, Velázquez C, et al. Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett 2010;20:4544–9.
- Chowdhury MA, Abdellatif KRA, Dong Y, et al. Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg Med Chem Lett 2009;19:6855–61.
- Abdellatif KRA, Abdelall EKA, Fadaly WA, Kamel GK. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,3,5-triarylpyrazoline and 1,5-diarylpyrazole derivatives as selective COX-2 inhibitors. Bioorg. Med Chem Lett 2016;26:406–12.
- Devarakonda M, Doonaboina R, Vanga S, et al. Synthesis of novel 2-alkyl-4-substituted-amino-pyrazolo [3, 4-d] pyrimidines as new leads for anti-bacterial and anti-cancer activity. Med Chem Res 2013;22:1090–101.
- Jones RG. Reactions of orthoesters with active methylene compounds. J Am Chem Soc 1952;74:4889–91.
- Heravi MM, Nami N, Seifi N, et al. Microwave-assisted synthesis of substituted pyrazoles and pyrazolo [3, 4-d] thiopyrimidines. Phosphorus Sulfur 2006;181:591–9.
- Behbehani H, Ibrahim HM. 4-Thiazolidinones in heterocyclic synthesis: synthesis of novel enaminones, azolopyrimidines and 2-Arylimino-5-arylidene-4-thiazolidinones. Molecules 2012;17:6362–85.
- Praveen Rao P, Amini M, Li H, et al. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J Med Chem 2003;46:4872–82.
- Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962;111:544–7.
- Cho CH, Ogle CW. Cholinergic-mediated gastric mast cell degranulation with subsequent histamine H1-and H2-receptor activation in stress ulceration in rats. Eur J Pharmacol 1979;55:23–33.